首页>投融资
Heranova Lifesciences
种子轮
Heranova Lifesciences是一家旨在为女性健康问题提供综合创新解决方案的医疗科技公司。公司计划通过整合诊断、药物、器械和数据,一站式解决妇产科领域未满足的医疗需求。公司也正积极开展针对内异症和妇科炎症的创新药物早期开发,并与全球合作伙伴共同拓展其他关键妇产科适应症的创新解决方案。
基本信息
-
公司全称Heranova Lifesciences Holding
-
类型女性健康问题综合创新解决方案提供商
-
产业领域药品研发/制造、器械/设备、试剂/耗材
-
公司人数101~500人
-
地址2 Burlington Woods Drive, Suite 100, Burlington, MA
-
联系电话1 (888)489-1808
-
邮箱info@heranovalifesciences.com
-
成立时间2022-06-01
投融资
-
2023-12-28种子轮1350万美元Emerging Technology Partners鼎丰生科资本/Pivotal bioVenture Partners China勤智资本Sinovation Ventures
-
2023-12-28种子轮1350万美元鼎丰生科资本勤智资本Sinovation VenturesETP Ventures
-
2023-03-08种子轮近千万美元创新工场鼎丰生科资本/Pivotal bioVenture Partners China
-
2023-03-08种子轮近千万美元创新工场鼎丰生科资本
- 加载更多
相关投融资企业
战略投资
Sofie Biosciences is a diagnostics company focused on developing technologies for PET in vivo molecular imaging.In May 2017, Sofie Biosciences entered into a definitive agreement under which it would buy Zevacor Pharma and its high-performance manufacturing and distribution network of PET imaging diagnostics and radio-therapeutics. The transaction was subject to closing conditions, which were expected to finalize in the next 60 to 90 days. In September 2017, the acquisition was completed to form SOFIE.In June 2016, the company completed a $3.7 million financing, representing an oversubscription of nearly $1 million
种子轮
Heranova Lifesciences是一家旨在为女性健康问题提供综合创新解决方案的医疗科技公司。公司计划通过整合诊断、药物、器械和数据,一站式解决妇产科领域未满足的医疗需求。公司也正积极开展针对内异症和妇科炎症的创新药物早期开发,并与全球合作伙伴共同拓展其他关键妇产科适应症的创新解决方案。
上市后再融资
Anpac Bio-Medical Science Co Ltd is a biotechnology company focused on early cancer screening and detection.In March 2023, the company had announced that it has entered into a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares (“ADSs”), pre-funded warrants to purchase ADSs and warrants to purchase ADSs in a registered direct offering.In February 2023, Anpac Bio-Medical Science Co Ltd through a subsidiary, Fresh Technology Inc entered into a definitive stock purchase agreement to acquire Fresh2 Ecommerce Inc.In July 2021, AnPac Bio-Medical Science Co had entered into an agreement with Advanced Life Therapeutics Co Ltd.In March 2023, Anpac Bio-Medical Science Co Ltd announced the private placement of 16,666,665 newly issued Class A ordinary shares of the company at a price of US$0.30 per ordinary share with gross proceeds of US$5 million.In January 2023, AnPac Bio-Medical Science announced sign